Just caught that Braidwell fund dumped like $75M worth of Xenon shares back in February - sold almost 1.8M shares when the stock was around $42. Interesting timing because Xenon was supposed to drop Phase 3 data in March for their seizure drug, which is kind of the whole bet here.

So now their position is down to 2.6% of the fund's total assets. Still meaningful but not a huge chunk anymore. The stock's only up like 6% over the past year which is honestly pretty weak for biotech - lots of other names have been flying. Makes you wonder if they got nervous about the clinical data or just wanted to trim risk.

Xenon's got a bunch of Phase 3 studies running for epilepsy treatments, and the data from that main trial is supposed to be huge for where this goes next. But here's the thing - when a big holder like Braidwell starts taking profits or reducing exposure before a major catalyst, it's worth paying attention to. Could mean they're hedging bets or just rebalancing. Either way, the March data timing and this sale happening just before it hit is worth noting if you're watching this stock.